Literature DB >> 9754655

Clonal deletion of thymocytes as a tumor escape mechanism.

G F Lauritzsen1, P O Hofgaard, K Schenck, B Bogen.   

Abstract

Clonal deletion of thymocytes is a major event in T-cell tolerance and might represent a tumor escape mechanism. Previously, we have shown that class II-restricted, Id-specific, CD4+ T cells in T-cell receptor (TCR)-transgenic mice confer resistance against the MOPC315 plasmacytoma. In this report, we have investigated whether monoclonal immunoglobulin (Ig) produced by a plasmacytoma can induce deletion of thymocytes specific for the variable parts of Ig, i.e., the idiotype (Id). Large numbers of MOPC315 tumor cells were injected s.c. in the TCR-transgenic mice to overwhelm the CD4+ T-cell-mediated protection. When the MOPC315 plasmacytomas reached a weight of approximately 0.5 g (serum myeloma protein M315 about 50 microg/ml), immature CD4+ 8+ and mature CD4+ transgenic thymocytes became progressively deleted. Apoptotic thymocytes were already detectable when tumors were 2 mm in diameter (serum M315: 5 microg/ml, or 0.03 microM). The negative selection was Id-specific, because an Id-negative plasmacytoma failed to induce deletion. Injection of purified MOPC315-myeloma protein (M315) i.p. caused a profound reduction of Id-specific thymocytes. Enriched thymic dendritic cells (DC) from tumor-bearing animals were found to be primed with lambda2(315) and induced apoptosis of thymocytes in vitro. Our results indicate that circulating myeloma protein is processed and presented by thymic antigen-presenting cells (APC), and induces deletion of Id-specific thymocytes. Deletion of tumor-specific thymocytes may represent a tumor escape mechanism in patients with cancers that secrete or shed tumor antigens. The possibility that vaccination with tumor Ig or genes encoding for it may induce tolerance instead of protection should be taken into consideration.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9754655     DOI: 10.1002/(sici)1097-0215(19981005)78:2<216::aid-ijc16>3.0.co;2-8

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells.

Authors:  Z Dembic; K Schenck; B Bogen
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

2.  Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model.

Authors:  Tullia C Bruno; Cristin Rothwell; Joseph F Grosso; Derese Getnet; Hung Rong Yen; Nicholas M Durham; George Netto; Drew M Pardoll; Charles G Drake
Journal:  Prostate       Date:  2011-07-14       Impact factor: 4.104

3.  Native IgG2a(b) is barely antigenic to major histocompatibility complex class II-restricted T cells owing to inefficient internalization by professional antigen-presenting cells.

Authors:  K Bartnes; K Hannestad
Journal:  Immunology       Date:  2000-04       Impact factor: 7.397

4.  Self-tolerance checkpoints in CD4 T cells specific for a peptide derived from the B cell antigen receptor.

Authors:  Thiago Detanico; Ryan A Heiser; Katja Aviszus; Cristina Bonorino; Lawrence J Wysocki
Journal:  J Immunol       Date:  2011-05-27       Impact factor: 5.422

5.  Circulating nucleic acids: An analysis of their occurrence in malignancies.

Authors:  Shankar Suraj; Chirag Dhar; Sweta Srivastava
Journal:  Biomed Rep       Date:  2016-11-16

6.  Novel role of CD8(+) T cells and major histocompatibility complex class I genes in the generation of protective CD4(+) Th1 responses during retrovirus infection in mice.

Authors:  Karin E Peterson; Ingunn Stromnes; Ron Messer; Kim Hasenkrug; Bruce Chesebro
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

Review 7.  T-helper cell tolerance to ubiquitous nuclear antigens.

Authors:  B Nakken; K E Davis; Z J Pan; M Bachmann; A D Farris
Journal:  Scand J Immunol       Date:  2003-11       Impact factor: 3.487

8.  SH2D2A modulates T cell mediated protection to a B cell derived tumor in transgenic mice.

Authors:  Tone Berge; Ingrid Helene Bø Grønningsæter; Kristina Berg Lorvik; Greger Abrahamsen; Stine Granum; Vibeke Sundvold-Gjerstad; Alexandre Corthay; Bjarne Bogen; Anne Spurkland
Journal:  PLoS One       Date:  2012-10-29       Impact factor: 3.240

9.  Novel process of intrathymic tumor-immune tolerance through CCR2-mediated recruitment of Sirpα+ dendritic cells: a murine model.

Authors:  Tomohisa Baba; Mohamed El Sherif Badr; Utano Tomaru; Akihiro Ishizu; Naofumi Mukaida
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

Review 10.  How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?

Authors:  Ole Audun Werner Haabeth; Anders Aune Tveita; Marte Fauskanger; Fredrik Schjesvold; Kristina Berg Lorvik; Peter O Hofgaard; Hilde Omholt; Ludvig A Munthe; Zlatko Dembic; Alexandre Corthay; Bjarne Bogen
Journal:  Front Immunol       Date:  2014-04-15       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.